Targeting BTK and Bcl-2 for B-Cell Malignancies: Where Are We Moving Toward?
Expert insights on the latest clinical findings on targeting Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (Bcl-2) to treat B-cell malignancies.
Credit available for this activity expires: 1/12/25
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/999658?ecd=bdc_podcast_libsyn_mscpedu
Create your
podcast in
minutes
It is Free